Document Type

Article

Publication Date

6-1-2017

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Molecular Cancer Research, Volume 15, Issue 6, June 2017, Pages 696-707.

The published version is available at https://doi.org/10.1158/1541-7786.MCR-16-0361. Copyright © American Association for Cancer Research

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the United States, whereas colorectal cancer is the third most common cancer. The RNA-binding protein HuR (ELAVL1) supports a pro-oncogenic network in gastrointestinal (GI) cancer cells through enhanced HuR expression. Using a publically available database, HuR expression levels were determined to be increased in primary PDA and colorectal cancer tumor cohorts as compared with normal pancreas and colon tissues, respectively. CRISPR/Cas9 technology was successfully used to delete the HuR gene in both PDA (MIA PaCa-2 and Hs 766T) and colorectal cancer (HCT116) cell lines. HuR deficiency has a mild phenotype,

Language

English

Included in

Surgery Commons

Share

COinS